North Star Investment Management Corp. Trims Stock Position in Humana Inc. $HUM

Key Points

• North Star Investment Management Corp. has significantly reduced its stake in Humana Inc. by 62.5%, leaving it with 600 shares valued at $147,000 as of the latest reporting period.
• Humana reported earnings of $6.27 per share, which was below analysts' expectations, although it achieved a quarterly revenue of $32.39 billion, surpassing predictions.
• The company recently announced a quarterly dividend of $0.885, translating to an annualized yield of 1.4%, with a payout ratio of 27.17%.

North Star Investment Management Corp. reduced its stake in Humana Inc. (NYSE:HUM - Free Report) by 62.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 600 shares of the insurance provider's stock after selling 1,000 shares during the quarter. North Star Investment Management Corp.'s holdings in Humana were worth $147,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Cary Street Partners Investment Advisory LLC grew its position in Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after buying an additional 46 shares during the last quarter. Riverview Trust Co acquired a new stake in shares of Humana in the 1st quarter worth $34,000. Garde Capital Inc. purchased a new stake in shares of Humana in the first quarter valued at about $36,000. Zions Bancorporation National Association UT acquired a new position in shares of Humana during the first quarter worth about $37,000. Finally, Whipplewood Advisors LLC raised its holdings in Humana by 639.1% during the first quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock worth $45,000 after purchasing an additional 147 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Stock Performance

Shares of HUM stock opened at $254.72 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The firm has a market capitalization of $30.64 billion, a price-to-earnings ratio of 19.55, a price-to-earnings-growth ratio of 1.50 and a beta of 0.44. Humana Inc. has a one year low of $206.87 and a one year high of $324.38. The company has a 50 day moving average price of $271.91 and a 200 day moving average price of $257.31.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion for the quarter, compared to analysts' expectations of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm's quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the firm earned $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. Sell-side analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, September 26th. Humana's dividend payout ratio (DPR) is 27.17%.

Wall Street Analyst Weigh In

HUM has been the topic of several recent analyst reports. Wells Fargo & Company dropped their target price on Humana from $348.00 to $344.00 and set an "overweight" rating on the stock in a research report on Thursday, August 14th. Royal Bank Of Canada upped their price objective on Humana from $283.00 to $322.00 and gave the stock an "outperform" rating in a report on Thursday, August 21st. Piper Sandler reduced their target price on Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a report on Thursday, July 31st. Robert W. Baird decreased their target price on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research report on Friday, July 25th. Finally, Bank of America increased their price target on shares of Humana from $285.00 to $312.00 and gave the company a "neutral" rating in a report on Tuesday, September 2nd. Seven equities research analysts have rated the stock with a Buy rating and seventeen have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $289.50.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.